How we work


The NHIC team members have strong track records in the identification and commercialization of intellectual property from academic, clinical and commercial fields (see Our Team). The depth and breadth of this experience is offered under each NHIC award, where their expertise and resources will be applied to the evaluation and nurturing of innovations along the commercialization pipeline.

NHIC will add value by adopting an active role in the mentoring of applicants and their respective teams at all stages, from early stage discussions through to the funding of the application and post-award management of projects (including progress against milestones and commercialization).

NHIC is able to bring in specialist consultants as required (in addition to funding awarded to the projects) to assist with regulatory information, business development etc as necessitated by the individual projects.

Through this committed involvement, NHIC aims to deliver the significant healthcare impact desired under the schemes.


I2P Applications

For details on I2P submission, please see I2P.

The I2P applications will be reviewed by the NHIC Review Panel, which comprises the NHIC team and selected external experts, before final approval from the Director of NHIC.

The target review periods are as follows:

  • Primary filing: 4-6 weeks
  • Secondary filing: 8-10 weeks

Once approved, patent filing is to be undertaken by the respective IP Office of the applicant’s institution and NHIC will reimburse costs.


I2D Applications

For details on I2D submission, please see I2D.

I2D applications will be reviewed by the NHIC Review Panel, which comprises the NHIC team and selected external experts. NHIC has several criteria for assessing a pre-proposal for shortlisting. Below are the categories and a brief note of what the reviewers will be seeking under each category.

Category Considerations
Background and preliminary data
  • Is there sufficient background to evaluate the scope and nature of the problem?
  • Is the unmet need clear?
  • Does the preliminary data support and de-risk further development of the technology?
  • Has the preliminary data been generated using the technology?
Development plan and deliverables
  • Is the development plan sensible and robust?
  • Are the deliverables realistic for the timeframe?
  • Are the deliverables attractive to a commercial partner (or a follow-on funder)?
  • Is the timeframe for obtaining ethics approvals appropriate?
Uniqueness of technology
  • How is the product/solution better than other options that are currently in use? Better, faster, cheaper?
Healthcare impact
  • Is the expected benefit of this technology clear?
  • How does the technology fit with current clinical practice/standard of care? Consider clinical adoption, patient benefit.
Commercial potential
  • Is the current IP status clear?
  • Consider the market size, route to market, competitive landscape.
Team composition
  • Does the team have (or able to access) the necessary competencies in: scientific and technological domains, clinical expertise, business development, where relevant?
  • Will recruitment of manpower impact project timelines?
Budget
  • Is the budget realistic for the work outlined?

The applicants of shortlisted I2D pre-proposals will be invited to submit a full proposal NHIC I2D Full Proposal Application Form and will have an opportunity to present a 15 minute innovator pitch to the NHIC Evaluation Panel.

NHIC will collaborate directly with the PI to develop the commercial framework, justification and valuation of the technology (the commitment of the PI will be an important determinant of success).

The NHIC Evaluation Panel, which comprises NHIC and external clinical, investment and commercial experts, will review the proposals before final approval by the NHIC Oversight Committee.

The target review period is 16 weeks.